Evidence map›Paper›PMID 25980620›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2015

Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation.

Alistair Taverner, Ruggero Dondi, Khaled Almansour, Floriane Laurent, Siân-Eleri Owens, Ian M Eggleston, Nikoletta Fotaki, Randall J Mrsny

Open access · hybridAbstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Review
  3. Gastrointestinal Permeation Enhancers Beyond Sodium Caprate and SNAC - What is Coming Next?Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  4. Review
  5. Recent advances in oral insulin delivery technologies.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. The strawberry-derived permeation enhancer pelargonidin enables oral protein delivery.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  10. Review
  11. Foundations of gastrointestinal-based drug delivery and future developments.Nature reviews. Gastroenterology & hepatology · 2022
    Review
  12. Article
  13. Cell-Penetrating Peptides as Carriers for Transepithelial Drug Delivery.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Nanocomposite systems for precise oral delivery of drugs and biologics.Drug delivery and translational research · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Alistair TavernerDepartment of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK.
Ruggero DondiDepartment of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK.
Khaled AlmansourDepartment of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK.
Floriane LaurentDepartment of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK.
Siân-Eleri OwensWelsh School of Pharmacy, Cardiff University, Cardiff, CF10 3XF, UK.
Ian M EgglestonDepartment of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK.
Nikoletta FotakiDepartment of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK.
Randall J MrsnyDepartment of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK. Electronic address: Rjm37@bath.ac.uk.
University of Bath · GBCardiff University · GB

Funding

Medical Research Council MC_PC_13058
6 · The paper itself

Abstract

The intestinal epithelium functions to effectively restrict the causal uptake of luminal contents but has been demonstrated to transiently increase paracellular permeability properties to provide an additional entry route for dietary macromolecules. We have examined a method to emulate this endogenous mechanism as a means of enhancing the oral uptake of insulin. Two sets of stable Permeant Inhibitor of Phosphatase (PIP) peptides were rationally designed to stimulate phosphorylation of intracellular epithelial myosin light chain (MLC) and screened using Caco-2 monolayers in vitro. Apical application of PIP peptide 640, designed to disrupt protein-protein interactions between protein phosphatase 1 (PP1) and its regulator CPI-17, resulted in a reversible and non-toxic transient reduction in Caco-2 monolayer trans-epithelial electric resistance (TEER) and opening of the paracellular route to 4kDa fluorescent dextran but not 70kDa dextran in vitro. Apical application of PIP peptide 250, designed to impede MYPT1-mediated regulation of PP1, also decreased TEER in a reversible and non-toxic manner but transiently opened the paracellular route to both 4 and 70kDa fluorescent dextrans. Direct injection of PIP peptides 640 or 250 with human insulin into the lumen of rat jejunum caused a decrease in blood glucose levels that was PIP peptide and insulin dose-dependent and correlated with increased pMLC levels. Systemic levels of insulin suggested approximately 3-4% of the dose injected into the intestinal lumen was absorbed, relative to a subcutaneous injection. Measurement of insulin levels in the portal vein showed a time window of absorption that was consistent with systemic concentration-time profiles and approximately 50% first-pass clearance by the liver. Monitoring the uptake of a fluorescent form of insulin suggested its uptake occurred via the paracellular route. Together, these studies add validation to the presence of an endogenous mechanism used by the intestinal epithelium to dynamically regulate its paracellular permeability properties and better define the potential to enhance the oral delivery of biopharmaceuticals via a transient regulation of an endogenous mechanism controlling the intestinal paracellular barrier.

Indexed as

AnimalsBiological TransportBlood GlucoseCaco-2 CellsHumansInsulinIntracellular Signaling Peptides and ProteinsMaleMuscle ProteinsMyosin-Light-Chain PhosphataseMyosin Light ChainsOligopeptidesPhosphoprotein PhosphatasesPhosphorylationRats, WistarBlood GlucoseInsulinIntracellular Signaling Peptides and ProteinsMuscle ProteinsMyosin-Light-Chain PhosphataseMyosin Light ChainsOligopeptidesPhosphoprotein PhosphatasesPPP1R12A protein, humanPPP1R14A protein, humanCell penetrating peptideInsulin deliveryMyosin light chain phosphataseParacellular transportProtein–protein interactionsTight junction function

Identifiers

PMID25980620
PMCPMC4504001
OpenAlexW323780170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.